Sartorius Stedim Biotech (OTCMKTS:SDMHF) Shares Up 1.6% – Should You Buy?

Sartorius Stedim Biotech S.A. (OTCMKTS:SDMHF) shares rose 1.6% during mid-day trading on Monday. The stock traded as high as $252.04 and last traded at $252.04. 1 shares traded hands during trading, a decline of 100% from the average session volume of 2,708 shares. The stock had previously closed at $248.00.

Analyst Upgrades and Downgrades

Separately, UBS Group upgraded Sartorius Stedim Biotech to a “buy” rating in a report on Thursday, August 20th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Sartorius Stedim Biotech presently has an average rating of “Moderate Buy”.

Sartorius Stedim Biotech Stock Performance

The firm’s 50-day moving average price is $238.44 and its 200 day moving average price is $212.60.

Sartorius Stedim Biotech Company Profile

Sartorius Stedim Biotech S.A. is a life sciences company that supplies technologies and services used by biopharmaceutical manufacturers. The company focuses on supporting the development and production of biological medicines, including vaccines, therapeutic proteins, and other advanced therapies. Its portfolio includes single-use bioprocessing equipment and consumables, bioreactors and fermentation systems, filtration and purification technologies, fluid-management products, cell-culture solutions, and equipment for filling and finishing pharmaceutical products.